April 21, 2016
Article
Novel therapy with indoximod, an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor, in combination with standard chemotherapy, yielded a response rate of 42% as first-line therapy for metastatic pancreatic adenocarcinoma
April 14, 2016
Article
Treatment with ensituximab (NPC-1C), a chimeric IgG1 monoclonal antibody, induced stable disease in nearly half of patients with chemotherapy-refractory metastatic colorectal cancer (mCRC) without contributing significant toxicity.
January 29, 2016
Article
In patients with chemotherapy-refractory metastatic colorectal cancer (mCRC), ensituximab (NPC-1C), a chimeric immunoglobulin IgG1 monoclonal antibody, produced stable disease in almost half the patients in a phase II study, without contributing toxicity.
January 27, 2016
Article
Patients with pancreatic adenocarcinoma enrolled on clinical trials have "profoundly improved survival" compared with patients in the general population, suggesting that oncologists who use trial data to prognosticate may be missing the mark, according to researchers whose work was presented at the 2016 Gastrointestinal Cancers Symposium.